Trial results for a Phase 3 study evaluating semaglutide for overweight and obesity were posted on ClinicalTrials.gov on 2026-05-18. The study demonstrated that participants receiving semaglutide 2.4 mg achieved a mean body weight reduction of -12.2%, compared to -2.2% in the placebo group.
Background
The study investigated semaglutide in individuals with overweight or obesity. The trial aimed to assess the efficacy of semaglutide in promoting weight loss compared to a placebo.
Trial design
The completed Phase 3 study (NCT06041217) enrolled 242 participants with overweight or obesity. The trial compared the weight loss in participants taking semaglutide to those taking a placebo over approximately one year. The study's objective was to evaluate how well semaglutide helps people with excess body weight to lose weight.
Key results
The trial reported the following key measurements:
- For Change in Body Weight (%):
- Participants receiving semaglutide 2.4 mg achieved a mean reduction of -12.2% (Standard Deviation 8.2).
- Participants receiving placebo achieved a mean reduction of -2.2% (Standard Deviation 5.4).
- For Number of Participants Who Achieved Body Weight Reduction ≥ 5%:
- 128 participants in the semaglutide 2.4 mg group.
- 19 participants in the placebo group.
- For Number of Participants Who Achieved Body Weight Reduction ≥ 10%:
- 96 participants in the semaglutide 2.4 mg group.
- 9 participants in the placebo group.
- For Change in Waist Circumference:
- Participants receiving semaglutide 2.4 mg achieved a mean reduction of -9.1 cm (Standard Deviation 6.2).
- Participants receiving placebo achieved a mean reduction of -2.4 cm (Standard Deviation 5.0).
Key analyses further supported these findings:
- The treatment difference for body weight reduction was -9.87 (95.0% Confidence Interval: -11.78 to -7.96), with a p-value of 0.0001.
- The Odds Ratio for achieving a body weight reduction of ≥ 5% was 14.83 (95.0% Confidence Interval: 7.42 to 29.63), with a p-value of 0.0001.
What this means
The results indicate that semaglutide 2.4 mg significantly reduced body weight and waist circumference in individuals with overweight or obesity compared to placebo. The substantial mean percentage change in body weight and the high odds ratio for achieving clinically meaningful weight loss (≥ 5%) suggest a strong therapeutic effect. These findings reinforce the potential of semaglutide as an effective treatment option for weight management in this population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT06041217, titled "A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range", were posted on 2026-05-18 on clinicaltrials.gov.